Tibotec

Tibotec is a pharmaceutical company with a focus on research and development for the treatment of infectious diseases such as HIV (AIDS), and Hepatitis C. The company develops antiretroviral drugs for the treatment of AIDS.

Additional recommended knowledge

Recognize and detect the effects of electrostatic charges on your balance

Correct Test Weight Handling Guide: 12 Practical Tips

Don't let static charges disrupt your weighing accuracy

History

In 1994, Rudi Pauwels (Rega Institute for Medical Research) founded Tibotec, together with his wife Carine Claeys, and their first co-workers Marie-Pierre de Béthune, Kurt Hertogs, and Hilde Azijn. In 1995 Paul Stoffels (Janssen Pharmaceutica) joins Tibotec. The company was acquired by Johnson & Johnson in April 2002. The name of the company is derived from the tetrahydro-imidazo[4,5,1-jk][1,4]-benzodiazepine-2(1H)-one and -thione (TIBO) compounds discovered at the Rega Institute for Medical Research (Belgium)^[1].

Drugs

• TMC114 (darunavir), a protease inhibitor (PI), (recently approved by the FDA)
• TMC125, (etravirine) a non-nucleoside reverse transcriptase inhibitor (NNRTI),
• TMC278, (rilpivirine) a NNRTI.

Tibotec licensed TMC120, a NNRTI, to the International Partnership for Microbicides for its development as a vaginal microbicide in March 2004.

References

1. ^ Pauwels R, Andries K, Desmyter J, Schols D, Kukla MJ, Breslin HJ, Raeymaeckers A, Van Gelder J, Woestenborghs R, Heykants J, et al., Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives, Nature, 1990, 343, 470-474. doi:10.1038/343470a0

See also

• Virco
• Galapagos Genomics
• Janssen Pharmaceutica
• FlandersBio